System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to HIV protease

1696 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-302-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-302-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  10-302-C025 azide free 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  10-302-C100 azide free 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  12-302-C100 low endotoxin 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell.
HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patents.


The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins.
The antibody 1696 does not react with the precursor.

Regulatory Status


Bacterially expressed full-length HIV-1 protease

Species Reactivity:

  • HIV

Negative Species:


  • Western Blotting
    Recommended dilution: 0.5 μg/ml
  • Functional Application
    The antibody 1696 strongly inhibits the enzyme activity of HIV-1 and HIV-2 proteases.
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Velazquez-Campoy A, Todd MJ, Vega S, Freire E: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7. [Abstract] [Full Text]
  • *Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber IT: Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry. 2007 Dec 25;46(51):14854-64. [Abstract]
  • *Brower ET, Bacha UM, Kawasaki Y, Freire E: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008 Apr;71(4):298-305. [Abstract]
  • *Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE: Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics. 2008 Apr 10;9(1):181 [Abstract] [Full Text]
  • Product Specific References

  • *Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA: Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 1999 Dec;8(12):2686-96. [Abstract]
  • *O'Loughlin TL, Greene DN, Matsumura I: Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol. 2006 Apr;23(4):764-72. [Abstract]
  • *Bartonová V, Král V, Sieglová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedlácek J, Rezácová P: Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 2008 Jun;78(3):275-7. Epub 2008 Feb 20. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse IgG1 Isotype Control
  • Example Data

    Fig. 1. Dot Blot

    Fig. 1. Dot Blot analysis of recombinant HIV protease.
    The total amount of recombinant HIV-protease spotted on the nitrocellulose membrane are indicated in left column.
    Lane 1: anti-HIV protease (1696); 0.2 μg/ml
    Lane 2: anti-HIV protease (1696); 1.0 μg/ml
    Lane 3: anti-HIV protease (1696); 2.0 μg/ml

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy